Amicus Therapeutics Inc (FOLD) Company Profile & Statistics

Amicus Therapeutics Inc
FOLD
(Nasdaq - US)
Open
10.31
+0.26 (+2.59%)
in:usd•As of: Oct 11, 2024 13:14 UTC -4
Open
10.04
High
10.36
Low
10.04

About Amicus Therapeutics Inc

CEO

Bradley L. Campbell

Headquarters

47 hulfish street

princeton, nj 08542, united states

Auditor

Ernst & YoungLLP

Employees

517

Share Holders

Website

www.amicusrx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.

Amicus Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	3.06B
Enterprise Value	3.24B
Enterprise Value/EBITDA (ttm)	-144.69
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	22.74
Price to Sales (ttm)	6.61
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	89.84%
Operating Margin (ttm)	-12.67%
Profit Margin (ttm)	-26.63%
Return on Equity (ttm)	-41.47%
Return on Invested Capital (ttm)	-22.61%
Return on Assets (ttm)	-7.66%

Income Statement

Revenue (ttm)	455.65M
Revenue Per Share (ttm)	1.54
Gross Profit (ttm)	409.56M
EBITDA (ttm)³	-22.38M
Net Income Avi to Common (ttm)	-119.54M
Diluted EPS (ttm)	-0.39

Share Statistics

Beta (5Y Monthly)	0.69
52-Week Change	-5.15%
S&P500 52-Week Change	32.70%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	296.59M
Dividend Yield	0.00%
Float ⁴	290.07M
% Held by Insiders	2.20%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	260.06M
Total Cash Per Share (mrq)	0.88
Total Debt (mrq)	388.94M
Total Debt/Equity (mrq)	293.49%
Current Ratio (mrq)	2.75%
Quick Ratio (mrq)	2.26%
Book Value Per Share (mrq)	0.45

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.02
Free Cash Flow (ytd)	-9.91M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Amicus Therapeutics Inc

Trade With A Regulated Broker